Publicaciones en colaboración con investigadores/as de Fred Hutchinson Cancer Research Center (56)

2023

  1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248

  2. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas

    Transplantation and Cellular Therapy, Vol. 29, Núm. 3, pp. 184.e1-184.e9

  3. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147

  4. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  5. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

    European Urology

2022

  1. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 20, Núm. 5, pp. e440-e452

  2. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

    BJU International, Vol. 130, Núm. 5, pp. 592-603

  3. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 20, Núm. 6, pp. 558-567

  4. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

    Breast Cancer Research, Vol. 24, Núm. 1

  5. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 31, Núm. 9, pp. 1863-1866

  6. Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))

    European journal of human genetics : EJHG

  7. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192

  8. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

    European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362

  9. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin

    Clinical Genitourinary Cancer, Vol. 20, Núm. 2, pp. 165-175

2021

  1. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 525-537

  2. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

    Breast cancer research : BCR, Vol. 23, Núm. 1, pp. 86

  3. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

    Blood, Vol. 138, Núm. 18, pp. 1768-1773

  4. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

    European Journal of Immunology, Vol. 51, Núm. 12, pp. 2708-3145

  5. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

    BJU International, Vol. 128, Núm. 2, pp. 196-205

  6. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

    Nature, Vol. 595, Núm. 7869, pp. 707-712